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Background: Extracellular vesicles (EVs) are small nanometre-sized vesicles that are circulating in blood. They
are released by multiple cells, including tumour cells. We hypothesized that circulating EVs contain protein
kinases that may be assessed as biomarkers during treatment with tyrosine kinase inhibitors.
Methods: EVs released by U87 glioma cells, H3255 and H1650 non-small-cell lung cancer (NSCLC) cells were
profiled by tandem mass spectrometry. Total AKT/protein kinase B and extracellular signal regulated kinase
1/2 (ERK1/2) levels as well as their relative phosphorylation were measured by western blot in isogenic U87
cells with or without mutant epidermal growth factor receptor (EGFRvIII) and their corresponding EVs. To
assess biomarker potential, plasma samples from 24 healthy volunteers and 42 patients with cancer were used.
Results: In total, 130 different protein kinases were found to be released in EVs including multiple drug
targets, such as mammalian target of rapamycin (mTOR), AKT, ERK1/2, AXL and EGFR. Overexpression
of EGFRvIII in U87 cells results in increased phosphorylation of EGFR, AKT and ERK1/2 in cells and
EVs, whereas a decreased phosphorylation was noted upon treatment with the EGFR inhibitor erlotinib.
EV samples derived from patients with cancer contained significantly more protein (p 0.0067) compared to
healthy donors. Phosphorylation of AKTand ERK1/2 in plasma EVs from both healthy donors and patients
with cancer was relatively low compared to levels in cancer cells. Preliminary analysis of total AKT and
ERK1/2 levels in plasma EVs from patients with NSCLC before and after sorafenib/metformin treatment
(n 12) shows a significant decrease in AKT levels among patients with a favourable treatment response
(pB0.005).
Conclusion: Phosphorylation of protein kinases in EVs reflects their phosphorylation in tumour cells. Total
AKT protein levels may allow monitoring of kinase inhibitor responses in patients with cancer.
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E
xtracellular vesicles (EVs) are nanometre-sized vesi-
cles released by cells into body fluids such as blood
and urine. They can be formed in the cytoplasm by
inwardbuddingofendosomalmembranesandsubsequent
fusionwiththeplasmamembrane(exosomes),ortheycanbe
shed directly from the plasma membrane (microvesicles)
(1 3). Importantly, EVs can be isolated from blood, cere-
brospinal fluid (CSF) and urine. Because they contain
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kinases such as AKT, EGFR (epidermal growth factor
receptor) and MET (4 6), EVs provide a potential bio-
source for diagnostics (7,8).
Kinases are important targets for treatment in patients
with cancer (9). However, not all patients respond fa-
vourably to kinase inhibitors and most patients acquire
drug resistance. Therefore, biomarkers that aid in predic-
tion and real-time monitoring of treatment responses in
patients could be of great value (10). The (re-)activation
of protein kinases in tumour cells promotes autopho-
sphorylation and has been associatedwith drug resistance
during treatment (11 13). A blood-based test providing
information on tumour kinase phosphorylation could
allow for longitudinal monitoring of drug resistance and
personalized treatment strategies. Here we hypothesized
that phosphorylation of protein kinases in EVs could serve
as a predictive biomarker during treatment with tyrosine
kinase inhibitors.
Materials and methods
Cells and compounds
H1650 (NCI-H1650; ATCC) and H3255 (NCI-H3255;
ATCC) non-small-cell lung cancer (NSCLC) cells were
maintained in RPMI-1640 (Lonza Biowhittaker, Verviers,
Belgium).The glioma cell lines U87 (U87MG; ATCC) and
U87-EGFRvIII (dr. Web Cavenee, Ludwig Cancer Inst.,
USA) were cultured in DMEM (Lonza Biowhittaker). All
cell culture media were supplemented with 10% foetal
bovine serum (FBS), 100 U/ml penicillin and 0.1 mg/ml
streptomycin, referred to as complete DMEM. EV-depleted
medium was obtained by 2 h ultracentrifugation of serum
at 100,000 g before use as a medium supplement. Drug
treatments were performed with erlotinib (LC Laborato
ries,Woburn,MA,USA)inDMEMcontainingEV-depleted
serum. Cell viability was assessed by 2 h incubation with
MTT 3-(4,5-dimethylthiazolyl-2)-2,5-diophenyl tetrazolium
bromide (Sigma-Aldrich, Zwijndrecht, The Netherlands).
Isolation of EVs
EVs were isolated from plasma or conditioned media as
described previously (14). Supernatants from cells, cul-
tured for 32 h in serum-free or with 10% EV-depleted
serum, were centrifuged at 500 g for 10 min to remove
cells. After another centrifugation step at 2,000 gf o r
15 min, the samples were concentrated by retention and
collection using 100 kDa cut-off filters (Amicon Ultra-15,
Millipore, Amsterdam, The Netherlands) and stored
at  208C. The precleared plasma samples were diluted
10-fold in PBS before ultracentrifugation. Centrifugation
at 10,000 g for 45 min was applied, before EVs were
pelleted by ultracentrifugation at 100,000 g for 90 min,
using a SW32TI rotor (Beckmann Instruments, Woerden,
The Netherlands). The EV pellet was treated with
proteases (0.5 g/L, Trypsin, Lonza Biowhittaker) or
erlotinib (10 mM) at 378C for 1 h when indicated.
Subsequently, EVs were washed in PBS followed by
centrifugation at 100,000 g for 90 min. All sequential
centrifugation steps were performed at 48C. Pellets were
solubilized in M-PER mammalian protein extraction
reagent, supplemented with phosphatase and protease
inhibitor cocktails (Pierce, Thermo Scientific, Breda, The
Netherlands).
LC-MS/MS analysis
EVs were isolated from 2 independent cell cultures
(10  T175) for each cell line and isolated as described
above. Full sample yield (corresponding to 10 15 mgo f
protein) was loaded on NuPAGE precast gradient gels,
and proteins were separated at 125 V. After electrophoresis,
gels were fixed in 50% ethanol containing 3% phosphoric
acid and stained with Coomassie R-250 and washed in
Milli-Q water (Supplementary Fig. 1). Gel lanes were cut
in 5 slices and each slice was processed by in-gel-digestion
according to the protocol previously published by
Shevchenko (15). Briefly, samples were treated with
dithiothreitol (10 mM) for 1 h at 568C and iodoacetamide
(50 mM) for 45 min at RT. The slices were dried and
incubated overnight with trypsin (6.25 ng/mL). Peptides
were extracted first in 1% formic acid and then in
50% ACN/5% formic acid. Subsequently, peptides were
separated by an Ultimate 3,000 nanoLC-MS/MS system
(Dionex LC-Packings, Amsterdam, The Netherlands).
After injection, peptides were trapped on a 10 mm 
100 mm ID trap column and separated at 300 nl/min in a
10 40% buffer gradient (80% ACN 0.05% formic acid)
in 60 min. Peptides were measured on-line after nanos-
pray ionization, using a Q Exactive mass spectrometer
(ThermoFisher, Bremen, Germany). Intact masses were
measured at resolution 70,000 (at m/z 200) in the orbi-
trap. MS/MS spectra were acquired at resolution 17,500
(at m/z 200) in the orbitrap using an AGC target value of
2 10
5 charges and an underfill ratio of 0.1%.
Protein identification and quantification
MS/MS spectrawere searched against the Uniprot human
referenceproteomeFASTAfile(releaseSept2012;147,951
entries) using MaxQuant 1.3.0.5 (default settings) (16).
Cysteine carboxamidomethylation was treated as fixed
modification and methionine oxidation and N-terminal
acetylation as variable modifications. Peptide and protein
identifications were filtered at an FDR of 1% using the
decoy database strategy. Proteins were quantified by
spectral counting (17,18), that is, the sum of all MS/MS
spectra for each identified protein. These counts were
normalized by dividing the spectral counts per protein by
the sum of all counts per sample and multiplying by the
average sum across all samples (18).
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analysis
For immunohistochemistry, cells were fixed in 2% para-
formaldehyde in PBS for 15 min. Permeabilization was
performed with ice-cold methanol (10 min), followed by
1 h incubation with 5% bovine serum albumin (BSA).
Staining with primary antibodies against EGFR (Cell
Signaling #2232, 1:200) or phospho-Y (4G10, Millipore,
USA, 1:200) was performed for 1 2 h at room tempera-
ture. Protein content of samples was determined with
the Micro BCA protein assay (Pierce, Thermo Scientific,
The Netherlands). For western blotting, equal protein
amounts or equal volumes (Fig. 1d) were used. Electro-
phoresis was performed on precast 4 12% SDS poly-
acrylamide gels (NuPAGE†, Life Technologies, Bleiswijk,
The Netherlands) and transferred to PVDF membranes
for immunoblotting of proteins. Membranes were probed
with antibodies against phospho-EGFR-y1068 (Cell
Signaling, Leiden, The Netherlands #2236s), EGFR (CS
#2232), phospho-AKT-s473 (CS #4051s), AKT (CS
#9272), phospho-ERK1/2-t202/204 (CS #9101s), ERK1/
2 (CS #9107s), a-tubulin (CS #2144s), Alix (CS #2171s),
CD63 (BD Bioscience, Etten-Leur, The Netherlands
556,019), cytochrome-C (BD Bioscience 556,433) and
GAPDH (CS #2118). IRDye infrared dye (LI-COR
Biosciences, Bad Homburg, Germany) labelled secondary
antibodies were used for detection. Membranes were
scanned using an Odyssey infrared imaging system and
accompanying software (version 3.0, Licor Biosciences).
Signal intensity was quantified using Image J imaging
analysis software (NIH, Bethesda, MD).
Study approval and plasma collection
All patients and/or their guardians gave written and oral
consent prior to providing blood for isolation of cir-
culating EVs. The protocol was approved by the Dutch
Competent Authority, Centrale Commissie Mensgebonden
Onderzoek (CCMO) and The Ethics Committee, Medisch
Etische Toesting Commissie (METC) VUmc (protocol
number: NL38229.029.11). We collected 12 ml of EDTA
blood (in 2  BD vacutainer #368661)   yielding 3 6.5
ml of plasma   from patients with various types of cancer
(n 32) and healthy donors (n 24). Samples were
centrifuged twice at 2,000 g for 10 min to remove cells
and frozen at  808C until further processing.
Statistical analysis
Statistical analysis was performed using the 2-tailed
(un)paired Student’s t-test embedded in Graphpad Prism
software (version 5.0 for Windows, GraphPad software,
CA, USA). For the survival analyses the log-rank test was
applied. All p-values B0.05 were considered significant.
Results
Protein kinases released in EVs from cancer
cell lines
We first investigated the variety and abundance of protein
kinases in EVs from different cell lines. EVs were isolated
from conditioned media of 2 NSCLC cell lines (H1650
and H3255) and U87 glioma cells, lysed and subjected
to tandem mass spectrometry. In total, 3,773 different
proteins were identified in at least 2 independent samples.
Marker proteins for exosomes such as TSG101, CD63,
FLOT1 and Alix were abundantly present in the samples
(see Supplementary Table I for full proteome results).
We next searched for protein kinases in the data set by
overlaying all protein IDs with publicly available protein
kinase IDs that were previously published (19). Kinases
were found from all 7 designated kinase groups (tyrosine
kinase, tyrosine kinase like, AGC, serine/threonine (STE),
CMCG, casein kinase 1, calcium and calmodulin 
dependent kinases), but also several kinases from atypical
classes (RGC, other) were present. EVs from U87 cells
contained 92 different kinases, while EVs from H1650
and H3255 NSCLC cells yielded, respectively, 85 and
106 protein kinases (Fig. 1). This analysis shows that the
majority of the kinases in EVs are present in EVs from
multiple cell lines.
As most clinically approved drugs, target kinases from
the tyrosine kinase group, we focused on this subset of
the kinome. Multiple kinases from the tyrosine kinase
group were found, with comparable representation (32 from
a total of 130 kinases) as in the human genome (90 from
518), suggesting rather random inclusion of protein kinases
during release of EVs. Both receptor tyrosine kinases
(EGFR, ERBB2, EPHA2, AXL, MET, PDGFR-B) as
well as non-receptor tyrosine kinases were present (SRC,
JAK1, FAK, YES1) in EVs (Table I). In addition multi-
ple cell cycle kinases (CDK2, PLK1 and AURKB) and
well-known drug targets were identified such as mTOR,
Fig. 1. Venn diagram of protein kinases detected in EVs from
3 different cell lines. All protein kinases were identiﬁed by a
cross search using protein IDs of the human kinome.
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different samples, average spectral counts are shown.
EGFR and EPHA2 were among the most prominent
receptor tyrosine kinases in EVs, while JAK1 and YES1
non-receptor tyrosine kinases were released with parti-
cular high levels. Wild-type EGFR was abundantly pre-
sent in both H3255 and U87 EVs. H3255 EVs uniquely
showed high levels of ERBB2, while only U87 EVs con-
tained PDGFRB. Also downstream mediators of these
receptors were detected. For example, AKT was found
in EVs from U87 and H3255 cells, while ERK1/2 was
present in all samples.
Protein kinase phosphorylation in cells and
EVs in vitro
We next investigated phosphorylation of protein kinases
in tumour cells and their EVs. Different receptor tyrosine
kinases were found to engage similar signalling compo-
nents, ultimately influencing a relatively small number of
downstream kinases (20,21). We reasoned that, in parti-
cular, the protein kinases AKT and ERK1/2 could be
valuable biomarkers as they reside downstream of multi-
ple oncogenic receptors that are currently being targeted
by drugs. AKTand ERK1/2 could therefore provide infor-
mation on activity of multiple receptor protein kinases.
To study differential phosphorylation, an isogenic human
cell line model was used, consisting of U87 glioma
cells with and without overexpression of the constitu-
tively active mutant kinase EGFR (EGFRvIII) (Fig. 2a).
Introduction of EGFRvIII in these cells enhances the
proliferation rate and results in increased sensitivity of
these cells to the EGFR inhibitor erlotinib (Fig. 2b).
IC50 values as measured by the MTT cell viability assay
were 8.5 mM for the parental cells and 2.3 mM for the
EGFRvIII cells (pB0.001). Impact of EGFRvIII on
phosphorylation of downstream targets was measured
by western blot. Increased phosphorylation of AKT and
ERK1/2 was found in cells expressing EGFRvIII in com-
parison to U87 parental cells (Fig. 2c). To visualize the im-
pact of erlotinib treatment on phosphorylation of AKT
and ERK1/2, quantification of the respective phospho-
staining intensity was performed (Fig. 2d). Treatment
of EGFRvIII cells with low concentrations of erlotinib
(1 mM) reduced phosphorylation of both AKT and
ERK1/2. In U87 parental cells in contrast, reductions
in phosphorylation were only noted at a 10-fold higher
concentration of erlotinib. No effect was found on EGFR,
AKT and ERK1/2 protein expression levels (Fig. 2c).
To further subtype the EVs released by U87 cells
in vitro, relative abundance of the exosome markers Alix,
CD63 and apoptotic marker cytochrome-C was measured
(Fig. 3a). Increased levels of CD63 and Alix were obser-
ved, while cytochrome-C was not detected in EV samples.
These results suggest a significant enrichment of exo-
somes in the EV pool. To determine whether EGFRvIII
expression influences EV production, protein yields from
isolations were measured. Total protein yield as measured
by the Micro BCA protein assay was normalized to
cell counts. No significant differences were observed in
the yield from the isolations of U87 cells or EGFRvIII-
containing cells (15.5 and 13.3 mg, respectively; Fig. 3b).
To investigate whether EVs could provide a read-out of
oncogenic signalling in cancer cells, EVs were isolated
from cells treated with erlotinib and subjected to western
blot. Total AKT and ERK1/2 protein levels were readily
detected by western blot, while EGFRwestern blot analy-
sis of EV samples appeared less efficient. Phosphorylation
as well as total protein levels of protein kinases was lower
Table I. Overview of average spectral counts for the tyrosine
kinases detected in extracellular vesicle samples from different
cell lines
Kinase H1650 H3255 U87
AXL 1 1 11
BLK 0 0 5
CSK 3 5 5
DDR1 0 17 0
DDR2 0 2 25
EGFR 20 587 137
EPHA1 0 7 0
EPHA2 46 61 66
EPHA4 0 9 1
EPHA5 0 0 1
EPHB2 2 30 67
EPHB3 0 19 0
EPHB4 2 98 1
ERBB2 0 126 0
ERBB3 0 10 0
FRK 0 6 0
FYN 0 10 18
IGF1R 0 8 5
INSR 0 9 5
JAK1 2 26 63
JAK2 0 0 1
LYN 2 49 16
MERTK 0 4 0
MET 2 22 21
MST1R 1 14 0
PDGRFB 0 0 12
PTK2 4 2 1
SRC 2 4 20
TYK2 0 15 19
YES1 6 51 45
AKT1
a 01 4 3
AKT2
a 04 2
MTOR
a 16 16 3
ERK1 (MAPK3)
a 24 6
ERK2 (MAPK1)
a 72 7 2 2
aNot tyrosine kinase.
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these cells were cultured on slides for immunostaining. Stainings were performed with EGFR and phospho-Yantibodies. (a) Sensitivity
of cell lines to the EGFR inhibitor erlotinib was determined in the MTT cell viability assay. (b) Subsequently, U87 and U87-EGFRvIII
cells were treated with increasing concentrations of erlotinib or DMSO vehicle. Phosphorylation of EGFR, AKT and ERK1/2
was analyzed by western blot. (c) Intensity of AKT and ERK1/2 phospho-stainings was quantiﬁed by Image J. Relative
phosphorylation during erlotinib treatment is shown. (d) To assess statistical signiﬁcance, the 2-tailed unpaired Student’s t-test was
applied. ***p50.001.
Fig. 3. EVs were isolated from U87 cells. To further characterize EVs, relative abundance of exosome markers Alix, CD63 and the
apoptotic marker cytochrome-C was analyzed by western blot. (a) EV protein yield from cells with or without EGFRvIII was deter-
mined by Micro BCA protein assay. Results were normalized to cell counts as measured by hemacytometer. (b) U87 cells with or
without EGFRvIII were treated with erlotinib and EVs were isolated. Phosphorylation of EGFR and downstream mediators AKTand
ERK1/2 in EVs was determined by western blot. U87 cells overexpressing EGFRvIII were used as positive control for immunostaining.
(c) Intensity of phosphostainings was quantiﬁed by Image J. Relative phosphorylation during treatment with erlotinib is shown.
(d) To assess statistical signiﬁcance, the 2-tailed unpaired Student’s t-test was applied. ns non-signiﬁcant.
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control for immunostaining. On the other hand, phos-
phorylation of EGFR, AKT and ERK1/2 kinases was
elevated in EVs from EGFRvIII cells in comparison to
EVs from parental U87 cells (Fig. 3c). Similar to what
was found in cells, treatment of the erlotinib-sensitive
U87-EGFRvIII cells with 1 mM erlotinib for 32 h resulted
in a decrease in phosphorylation of AKT and ERK1/2
in EVs. However, in the EVs from the erlotinib-resistant
parental U87 cells only a modest reduction in phosphor-
ylation was observed at a 10-fold higher erlotinib dose
(Fig. 3c and d). Altogether these results indicate that the
phosphorylation profiles of AKT and ERK1/2 kinases in
EVs may reflect the intracellular phosphorylation status
during treatment with erlotinib.
In order to determine whether the double-layered
membranes of EVs protect their content from proteases,
EVs were incubated with proteases, erlotinib and PBS-
control. Protease treatment caused small changes in kinase
protein levels in EVs. In whole cells lysates in contrast,
complete digestion was observed after 1 h of treatment
(Fig. 4). Simultaneously, a reduction of the Alix levels
was found in the protease treated samples. These results
suggest that structure and/or stability of EVs may be
affected by proteases. Short-term exposure of the EVs to
high concentrations of erlotinib (10 mM) had no effect on
either phosphorylation or total protein levels in the EVs
(Fig. 4). Altogether we conclude that AKT and ERK1/2
protein kinases reside within EVs, which protects them
from potential detrimental influences of enzymes in the
circulation.
Protein kinase phosphorylation in blood
derived EVs
We next investigated whether AKT and ERK1/2 kinase
phosphorylation may be used as biomarker in patients
with cancer. Since limited information is available on the
production of EVs by different cancer cells, a cohort of 42
patientswas recruitedwith avarietya cancer types (Table II).
Three patients with oesophageal cancer, 3 patients with
breast cancer, 21 patients with NSCLC and 4 patients
with glioma were included among others (Table II).
Thirty-three patients (76%) had metastatic disease, while
9 patients (21%) had either glioma or localized disease.
At the time, the first blood samples were obtained none of
the patients received active systemic treatment.
First, EV protein levels in blood of healthy volunteers
(n 22) and the patients with cancer were measured.
Plasma samples were diluted in PBS, and EVs were
isolated. EV proteinyield from each sample was measured
using the Micro BCA protein assay (Fig. 5a). EV samples
derived from patients with cancer contained significantly
more protein (p 0.0067) compared to healthy donors.
In 6 patients, increased EV protein levels were observed.
Two of these patients had NSCLC, while the others had
CRC, SCLC, oesophageal cancer and RCC. Five out
of six patients were diagnosed with metastatic disease.
No significant difference was detected in the amount of
EV protein between patients with metastatic disease and
patients with localized disease (p 0.78) (Fig. 5b).
Subsequently, AKT and ERK1/2 protein levels and
their phosphorylation status in circulating EVs in patients
and healthy donorswere determined. Western blot analysis
was performed using equal protein amounts from 21
randomly selected patients and 22 healthy donors. Total
AKT protein was readily detected in all EV samples,
whereas total ERK1/2 levels showed more variation be-
tween samples (Fig. 5c, d and Supplementary Fig. 2).
Alix staining was not detectable in EV samples iso-
lated from plasma, whereas GAPDH staining was high
(Supplementary Fig. 1). Subsequently, phosphorylation
of AKT and ERK1/2 was measured in EV samples from
both patients as well as healthy volunteers. As compared
to phosphorylation levels of these proteins in cancer cells,
phosphorylation of AKT and ERK1/2 was relatively low
(Fig. 5c e). Semi-quantification of phosphorylation was
performed by calculating the relative signal intensity from
phosphorylated and total protein levels. No significant
differences were observed in the phosphorylation status
of AKT and ERK1/2 between patients with cancer
and healthy volunteers, p 0.78 and p 0.76, respectively
(Fig. 5d and e). Additionally, the subgroup of patients
with high protein levels did not demonstrate increased
AKT (p 0.56) or ERK1/2 phosphorylation (p 0.98)
as compared to the healthy donors (Fig. 5d and e). To
determine variability in total EV kinase levels in plasma,
maximum protein amounts were loaded from a subgroup
Fig. 4. EVs were isolated from culture medium of an equal
number of U87 cells with or without EGFRvIII. EV pellets were
treated with proteases (trypsin, 0.5 g/L) or erlotinib (10 mM) for
1ha t3 7 8C. Subsequently, EVs were washed in PBS and lysed.
Western blot analysis was performed using equal volumes to
determine protein levels and their phosphorylation. U87 cells
overexpressing EGFRvIII were used as positive control for
immunostaining.
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Sample type Mean age (9SD) Gender (% male) Metastatic disease (%)
Healthy donors (n 22) 49.5 (9.9) 12 (55)  
Non-small-cell lung cancer (NSCLC) (n 21) 57.9 (12.3) 11 (52) 20 (95)
Glioma (n 4) 68.8 (4.9) 2 (50) 0 (0)
Breast cancer (n 3) 52 (8.2) 0 (0) 2 (67)
Oesophageal cancer (n 3) 55 (1) 2 (67) 2 (67)
Colorectal cancer (n 2) 67.5 (14.8) 2 (100) 2 (100)
Cholangio cancer (n 2) 62.5 (13.4) 1 (50) 1 (50)
Endometrial cancer (n 1) 63 0 (0) 1 (100)
Pancreatic cancer (n 1) 64 0 (0) 0 (0)
Renal cell cancer (n 1) 52 1 (100) 1 (100)
Melanoma (n 1) 61 0 (0) 1 (100)
Small-cell lung cancer (SCLC) (n 1) 77 0 (0) 1 (100)
Ewing sarcoma (n 1) 49 1 (100) 1 (100)
Cancer of unknown primary (n 1) 71 1 (100) 1 (100)
Fig. 5. Plasma was collected from 32 patients with cancer and 28 healthy donors. Total protein yield from each isolation was measured
by the Micro BCA protein assay. (a b) Phosphorylation of AKT and ERK1/2 was measured by western blot using equal protein
amounts from 21 patients and 22 healthy donors. U87 cells overexpressing EGFRvIII were used as positive control for immunostaining.
(c) Signal intensities were quantiﬁed by Image J imaging analysis software and phosphorylation was measured by calculating the
relative signal intensity from phosphorylated and total protein levels. Subgroup analysis was performed with patients having high EV
protein levels as shown in red. (a, d e) To determine variability in total EV kinase levels in plasma, maximum protein amounts were
loaded from a subgroup of patients with NSCLC. (f) Statistical signiﬁcance was tested using the 2-tailed paired Student’s t-test. ns not
signiﬁcant, *p50.05, **p50.01, ***p50.001.
Analysis of AKT and ERK1/2 in EVs
Citation: Journal of Extracellular Vesicles 2014, 3: 25657 - http://dx.doi.org/10.3402/jev.v3.25657 7
(page number not for citation purpose)of patients with NSCLC. Substantial variation in total
AKT and ERK1/2 levels were noted in EVs from these
patients (Fig. 5f).
Total AKT levels in EVs correlate with response
to sorafenib/metformin treatment
A subgroup of 12 patients with KRAS mutated NSCLC
(n 12) were included in an on-going single arm phase
II study (more detailed information can be found in
Supplementary Table II). Based on the KRAS mutation
status, patients were selected for treatment with sorafenib
and metformin. Sorafenib is a small molecule tyrosine
kinase inhibitor, which inhibits angiogenesis in tumours
through blockade of VEGFR2/3 and PDGF receptors.
In addition, it is known to have affinity for CRAF and
BRAF, both mediators downstream of KRAS. Metformin,
on the other hand, reduces systemic glucose and insulin
levels, thereby interfering with insulin/insulin-like growth
factor receptor (IGFR1) signalling in cancer cells. Since
AKT and ERK1/2 act downstream of IGFR1 and RAS/
RAF, respectively, EV protein levels were investigated
as potential predictive biomarkers. Consistent with pre-
vious results both before and during treatment, phosphor-
ylation in EVs was low (data not shown). Before and
3 weeks after onset of treatment, CT scans and blood
plasma samples were collected. Treatment with sorafenib/
metformin resulted in partial response/stable disease or
progressive disease (PD) at 3 weeks according to RECIST
criteria (Fig. 6a). Median progression free survival (PFS)
of the favourable response group was 4.1 months (95% CI
0.6 7.5), while the resistant group responded for only
0.8 months (95% CI 0.7 0.8). Overall survival of the
favourable response group was 6.5 months(95% CI 3.1 9.9),
while the patients with PD survived for only 2.1 months
(95% CI 0.3 3.9). Plasma EVs were isolated and samples
were subjected to western blot analysis of AKT and
ERK1/2 protein levels (Fig. 6b). Protein levels at baseline
and during treatment were quantified and correlated to
the treatment response (Fig. 6c). AKT was detected in
plasma EV samples of all patients (n 12). No reduction
in the AKT and ERK1/2 protein levels in EVs were
observed during treatment with sorafenib/metformin in
patients with PD at 3 weeks. However, in patients with
partial response/stable disease (n 7), significant reduc-
tions were observed in AKT protein levels in plasma EVs
(pB0.005, Fig. 6b and c). Similarly, ERK1/2 levels in
EVs decreased during treatment in patients with a favour-
able treatment response; however, this difference did not
Fig. 6. Representative CT images of patient #7 at baseline and with stable disease (SD) at 3 weeks on sorafenib/metformin and of
patient #9 at baseline and with progressive disease (PD) at 3 weeks on sorafenib/metformin. (a) Western blot analysis was performed of
plasma EVs of NSCLC patients (n 12). (b) Total AKTand ERK1/2 levels in EVs, 3 weeks after start of treatment, are shown. Patients
with PD and SD or partial response (PR) on sorafenib/metformin treatment are grouped. (b) Samples are paired pre- and on-treatment
samples depicted with   and  , respectively. Signal intensities were quantiﬁed by Image J imaging analysis software. (c) Kaplan Meier
curves were generated for the treatment response (PFS) of patients with stable and decreased AKT and ERK1/2 levels in EVs. (c d)
To assess statistical signiﬁcance, the 2-tailed unpaired t-test was applied. *pB0.001, **pB0.0001. The log-rank test was used for
statistical analysis of survival analyses.
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clude that substantial variation is observed in AKT
and ERK1/2 protein levels in EVs particularly during
treatment with sorafenib/metformin. AKT protein levels
in EVs may serve as potential predictive biomarker for
the response of patients with NSCLC to sorafenib and
metformin.
Discussion
We found that EVs contain multiple protein kinases and
that their phosphorylation corresponds to the profile
in tumour cells in vitro. In addition, preliminary evalua-
tion of EV associated AKT protein levels in patients
reveals a correlation with response to sorafenib/metformin
treatment.
Presence of multiple tumour-derived drug targets in
EVs suggests potential as biomarker platform. Several
techniques have been developed to predict and monitor
effects of kinase inhibitors. Mutational analysis of genes
encoding kinase inhibitor targets, such as EGFR and
BRAF in tumour tissue biopsies, proved to be a powerful
tool to predict treatment response in patients with
NSCLC and melanoma (22,23). Tumour mutations are
also readily detectable in several blood compartments
such as plasma, EVs and blood platelets (8,24,25),
allowing for non-invasive diagnostics. Important advan-
tage of blood-based biomarkers is that they are easily
available and also allow longitudinal monitoring during
treatment. Mutations in DNA or RNA are stable and
tumour specific, but biological effects may be hampered
by, for example methylation or RNA interference. Protein
levels and protein phosphorylation, in contrast, directly
correlate with biological effects in cells, yielding powerful
biomarkers (26). Circulating peptide and protein signatures
were also shown to be predictive for treatment response
(27 30).
Previous studies indicated that upon treatment with
small molecule kinase inhibitors, multiple modulations
of phosphorylation occur in tumours of patients (31,32).
For example, in tumour biopsies from patients with gastric
cancer, a reduction in AKT phosphorylation was found,
with an interesting association with apoptosis (33).
Another study, investigating EVs as potential biomarker
platform, indicated that analysis of protein levels in EVs
allows real-time monitoring of treatment effects induced
in tumours in vivo (7). Here, we show that proteins in EVs
are protected against external influences and also that
post-translational modifications such as phosphorylation
are conserved. Moreover, our in vitro data suggest that
circulating EVs may provide a read-out of oncogenic
signalling in tumour cells. However, despite very high
phosphorylation in cancer cells, we found relatively low
phosphorylation of AKT and ERK1/2 in plasma EVs.
Since phosphorylation was low, but fairly detectable in
cell culture samples, it is unlikely that phosphorylation is
lost during the vesicle isolation. Levels in healthy donors
suggest that AKT and ERK1/2 studies may suffer from
a high background of vesicles released by other cells.
Therefore, it should be evaluated whether more tumour-
specific proteins may give lower background and there-
fore are more attractive as a biomarker. Because of
the role of AKT and ERK1/2 in signalling of multiple
receptor tyrosine kinases, phosphorylation of these pro-
teins in cells as well as their EVs may still be of great
interest. Although we found that phosphorylation of AKT
and ERK1/2 in EVs is low, it remains to be investigated
whether this event has any value as a biomarker. For such
a study, it is important to develop a more sensitive and
specific method for quantitative measurements of phos-
phorylated proteins in EVs. These may be based on, for
example, ELISA, mNMR, peptide array or mass spectro-
metry techniques (7,34).
Current EV isolation methods typically yield relatively
low protein levels, which limits protein biomarker studies.
For clinical applications, the EV studies may benefit from
a simple and robust isolation strategy that also allows
specific isolation of tumour-derived EVs from blood.
Flow cytometry methods have been described, but may be
particularly beneficial for the larger vesicles (e.g. apoptotic
bodies) (35). Capture-based isolation procedures are con-
venient but use surface markers to specifically bind
subsets of EVs (exosomes, microvesicles), and this may
also bias and limit biomarker studies. We did not detect
Alix in our plasma EV analysis, while in our in vitro
analysis a pronounced exosome signature was noted in
the EV samples with abundant Alix, TSG101 and CD63.
To the best of our knowledge, it is currently unknown
which subtype of EVs contains the most clinically useful
biomarkers. Future biomarker research may therefore
also benefit from further subtyping of the different EVs.
Combinations of antibodies against EV subtype markers
(e.g. CD63, cytochrome-C) with antibodies raised against
epitopes exclusively present on mutant proteins (36) may
help in isolation of tumour-specific EVs.
We found increased EV protein amounts in patients
with cancer compared to healthy volunteers. In our
sorafenib/metformin analysis, high AKT levels during
treatment were associated with treatment failure and
poor survival. MET protein levels in EVs were previously
found to be correlated with overall survival of patients
with melanoma (5). These results suggest that high kinase
levels in EVs are a poor prognostic feature in patients
with cancer. It would be of interest to investigate the
value of EV counts as well as EV protein amounts both
at baseline as well as during treatment, in conjunction
with protein kinase levels as biomarker. The biomarker
analysis also showed downmodulation of total AKT and
to some extent ERK1/2 protein levels during treatment
with sorafenib/metformin. Unfortunately, no tumour tissue
samples were available for comparative analyses between
Analysis of AKT and ERK1/2 in EVs
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be related to direct biological effects of the treatment on
tumour cells or reflect a mere systemic response remains
enigmatic. However, this analysis warrants further in-
vestigation and proves potential of protein kinase levels
as biomarker in patients with cancer.
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